Objective: In patients with intermediate- and high-risk localized prostate cancer (PCa), improving the detection of occult lymph node metastases could play a pivotal role for therapeutic counseling and planning. The recent literature shows that several clinical factors may be related to PCa aggressiveness. The aim of this study is to investigate the potential associations between clinical factors and the risk of multiple lymph node invasion (LNI) in patients with intermediate- and high-risk localized PCa (cT1/2, cN0, and ISUP grading group >2 and/or prostate-specific antigen (PSA) >10 ng/mL) who underwent radical prostatectomy (RP) and extended pelvic lymph node dissection (ePLND). Materials and Methods: In a period ranging from January 2014 to December 2018, 880 consecutive patients underwent RP with ePLND for PCa. Among these, 481 met the inclusion criteria and were selected. Data were prospectively collected within an institutional dataset and retrospectively analyzed. Age (years), body mass index (BMI; kg/m2), PSA (ng/mL), prostate volume (mL), and biopsy positive cores (BPC; %) were recorded for each case. BMI and BPC were considered continuous and categorical variables, respectively. The logistic regression models evaluated the association of clinical factors with the risk of nodal metastases. Results: LNI was detected in 73/418 patients (15.2%) of whom 40/418 (8.3%) harbored multiple LNI (median 2, IQR: 3–4). On multivariate analysis, BMI was independently associated with the risk of multiple LNI in the pathological specimen when compared with patients without LNI (OR = 1.147; p = 0.018), as well as the percentage of biopsy positive cores (OR = 1.028; p < 0.0001) and European Association of Urology high-risk class (OR = 5.486; p < 0.0001). BMI was the only predictor of multiple LNI when compared with patients with 1 positive node (OR = 1.189, p = 0.027). Conclusions: In intermediate- and high-risk localized PCa, BMI was an independent predictor of the risk of multiple lymph node metastases. The inclusion of BMI within LNI risk calculators could be helpful, and a detailed counseling in obese patients should be required.

1.
Ferlay
J
,
Soerjomataram
I
,
Dikshit
R
,
Eser
S
,
Mathers
C
,
Rebelo
M
, et al.
Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012
.
Int J Cancer
.
2015
;
136
(
5
):
E359
86
.
2.
Mottet
N
,
Bellmunt
J
,
Bolla
M
,
Briers
E
,
Cumberbatch
MG
,
De Santis
M
, et al.
EAU-ESTRO-SIOG Guidelines on prostate cancer. Part 1: screening, diagnosis, and local treatment with curative intent
.
Eur Urol
.
2017
;
71
(
4
):
618
29
.
3.
Epstein
JI
,
Egevad
L
,
Amin
MB
,
Delahunt
B
,
Srigley
JR
,
Humphrey
PA
.
The 2014 International Society of Urological Pathology (ISUP) consensus conference on Gleason grading of prostatic carcinoma
.
Am J Surg Pathol
.
2016
;
40
(
2
):
244
52
.
4.
Hövels
AM
,
Heesakkers
RA
,
Adang
EM
,
Jager
GJ
,
Strum
S
,
Hoogeveen
YL
, et al.
The diagnostic accuracy of CT and MRI in the staging of pelvic lymph nodes in patients with prostate cancer: a meta-analysis
.
Clin Radiol
.
2008
;
63
(
4
):
387
95
.
5.
von Eyben
FE
,
Kairemo
K
.
Meta-analysis of (11)C-choline and (18)F-choline PET/CT for management of patients with prostate cancer
.
Nucl Med Commun
.
2014
;
35
(
3
):
221
30
.
6.
Porcaro
AB
,
De Luyk
N
,
Corsi
P
,
Sebben
M
,
Tafuri
A
,
Processali
T
, et al.
Clinical factors predicting bilateral lymph node invasion in high-risk prostate cancer
.
Urol Int
.
2017
;
99
(
4
):
392
9
.
7.
Porcaro
AB
,
Inverardi
D
,
Corsi
P
,
Sebben
M
,
Cacciamani
G
,
Tafuri
A
, et al.
Prostate-specific antigen levels and proportion of biopsy positive cores are independent predictors of upgrading patterns in low-risk prostate cancer
.
Minerva Urol Nefrol
.
2020
;
72
(
1
):
66
71
.
8.
Bandini
M
,
Gandaglia
G
,
Briganti
A
.
Obesity and prostate cancer
.
Curr Opin Urol
.
2017
;
27
(
5
):
415
21
.
9.
Committee WE
.
Physical status: the use and interpretation of anthropometry
;
1995
.
Available from
: http://helid. digicollection. Org/en/d/Jh0211e/.
10.
Carroll
PH
,
Mohler
JL
.
NCCN guidelines updates: prostate cancer and prostate cancer early detection
.
J Natl Compr Canc Netw
.
2018
;
16
(
5S
):
620
3
.
11.
Porcaro
AB
,
Tafuri
A
,
Novella
G
,
Sebben
M
,
Mariotto
A
,
Inverardi
D
, et al.
Inverse association of prostatic chronic inflammation among prostate cancer tumor grade groups: retrospective study of 738 consecutive cases elected to a first random biopsy set
.
Urol Int
.
2018
;
100
(
4
):
456
62
.
12.
Menon
M
,
Tewari
A
,
Peabody
J
;
Members of the VIP team
.
Vattikuti Institute prostatectomy: technique
.
J Urol
.
2003
;
169
(
6
):
2289
92
.
13.
Walsh
PC
.
Anatomic radical prostatectomy: evolution of the surgical technique
.
J Urol
.
1998
;
160
(
6 Pt 2
):
2418
24
.
14.
Cacciamani
GE
,
Porcaro
AB
,
Sebben
M
,
Tafuri
A
,
Rizzetto
R
,
De Luyk
N
, et al.
Extended pelvic lymphadenectomy for prostate cancer: should the Cloquet’s nodes dissection be considered only an option?
Minerva Urol Nefrol
.
2019
;
71
(
2
):
136
45
.
15.
Porcaro
AB
,
Cacciamani
GE
,
Sebben
M
,
Tafuri
A
,
Processali
T
,
Rizzetto
R
, et al.
Lymph nodes invasion of Marcille’s Fossa Associates with high metastatic load in prostate cancer patients undergoing extended pelvic lymph node dissection: the role of “Marcillectomy”
.
Urol Int
.
2019
;
103
(
1
):
25
32
.
16.
Srigley
JR
,
Humphrey
PA
,
Amin
MB
,
Chang
SS
,
Egevad
L
,
Epstein
JI
, et al.
Protocol for the examination of specimens from patients with carcinoma of the prostate gland
.
Prostate
.
2012
;
3
.
17.
Fossati
N
,
Willemse
PM
,
Van den Broeck
T
,
van den Bergh
RCN
,
Yuan
CY
,
Briers
E
, et al.
The benefits and harms of different extents of lymph node dissection during radical prostatectomy for prostate cancer: a systematic review
.
Eur Urol
.
2017
;
72
(
1
):
84
109
.
18.
Boorjian
SA
,
Thompson
RH
,
Siddiqui
S
,
Bagniewski
S
,
Bergstralh
EJ
,
Karnes
RJ
, et al.
Long-term outcome after radical prostatectomy for patients with lymph node positive prostate cancer in the prostate specific antigen era
.
J Urol
.
2007
;
178
(
3 Pt 1
):
864
1
.
19.
Moris
L
,
Van den Broeck
T
,
Tosco
L
,
Van Baelen
A
,
Gontero
P
,
Karnes
RJ
, et al.
Impact of lymph node burden on survival of high-risk prostate cancer patients following radical prostatectomy and pelvic lymph node dissection
.
Front Surg
.
2016
;
3
:
65
.
20.
Schumacher
MC
,
Burkhard
FC
,
Thalmann
GN
,
Fleischmann
A
,
Studer
UE
.
Good outcome for patients with few lymph node metastases after radical retropubic prostatectomy
.
Eur Urol
.
2008
;
54
(
2
):
344
52
.
21.
Touijer
KA
,
Mazzola
CR
,
Sjoberg
DD
,
Scardino
PT
,
Eastham
JA
.
Long-term outcomes of patients with lymph node metastasis treated with radical prostatectomy without adjuvant androgen-deprivation therapy
.
Eur Urol
.
2014
;
65
(
1
):
20
5
.
22.
Heidenreich
A
,
Varga
Z
,
Von Knobloch
R
.
Extended pelvic lymphadenectomy in patients undergoing radical prostatectomy: high incidence of lymph node metastasis
.
J Urol
.
2002
;
167
(
4
):
1681
6
.
23.
Porcaro
AB
,
Cavicchioli
F
,
Mattevi
D
,
De Luyk
N
,
Corsi
P
,
Sebben
M
, et al.
Clinical factors of disease reclassification or progression in a contemporary cohort of prostate cancer patients elected to active surveillance
.
Urol Int
.
2017
;
98
(
1
):
32
9
.
24.
Di Francesco
S
,
Robuffo
I
,
Caruso
M
,
Giambuzzi
G
,
Ferri
D
,
Militello
A
, et al.
Metabolic alterations, aggressive hormone-naive prostate cancer and cardiovascular disease: a complex relationship
.
Medicina
.
2019
;
55
(
3
):
62
.
25.
Tafuri
A
,
Sebben
M
,
Shakir
A
,
Pirozzi
M
,
Processali
T
,
Rizzetto
R
, et al.
Endogenous testosterone mirrors prostate cancer aggressiveness: correlation between basal testosterone serum levels and prostate cancer European Urology Association clinical risk classes in a large cohort of Caucasian patients
.
Int Urol Nephrol
.
2020
:
52
(
7
):
1261
9
.
26.
Wang
K
,
Chen
X
,
Bird
VY
,
Gerke
TA
,
Manini
TM
,
Prosperi
M
.
Association between age-related reductions in testosterone and risk of prostate cancer-an analysis of patients’ data with prostatic diseases
.
Int J Cancer
.
2017
;
141
(
9
):
1783
93
.
27.
Porcaro
AB
,
Sebben
M
,
Tafuri
A
,
de Luyk
N
,
Corsi
P
,
Processali
T
, et al.
Body mass index is an independent predictor of Clavien-Dindo grade 3 complications in patients undergoing robot assisted radical prostatectomy with extensive pelvic lymph node dissection
.
J Robot Surg
.
2019
;
13
(
1
):
83
9
.
28.
Pfitzenmaier
J
,
Pritsch
M
,
Haferkamp
A
,
Jakobi
H
,
Fritsch
F
,
Gilfrich
C
, et al.
Is the body mass index a predictor of adverse outcome in prostate cancer after radical prostatectomy in a mid-European study population?
BJU Int
.
2009
;
103
(
7
):
877
82
.
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.